Drug Price Impact of UK-US Trade Deal Comes Under Scrutiny
House of Lords Examines Effects Of FTA On UK Industry And NHS
Executive Summary
A month after the UK and the US began talks on a future free trade agreement, a new House of Lords committee says that an FTA involves risks as well as benefits, and has stakeholders to give their views on the likely impact of a deal in areas like drug pricing and the NHS.
You may also be interested in...
UK's Post-Brexit Medicine Plans Under Pressure
UK proposals for limited cooperation with the EU in medicines regulation, including the recognition of certificates and inspections, are one glimmer of light in an otherwise uncertain post-Brexit regulatory scenario for the UK. But time pressures and political spats over the future relationship could throw the whole enterprise into doubt.
UK Gov't Disowns ‘Secret’ Meetings With US On Post-Brexit Drug Pricing
Brexit and the NHS are likely to be key issues as political parties in the UK prepare to campaign ahead of the general election in December.
New Zealand Hikes Fees To Reflect Changes In Drug Applications
Following a consultation last year, Medsafe has set new fee levels that take account of both cost-recovery principles and a 4.2% increase in the consumer price index.